LACTOLOGY FOUNDATION

Academic Review of Testicular Physiology, Pathophysiology of Testicular Disorders, and Contemporary Clinical Management

Physiology of Testicular Function and Endocrine Regulation

The Hypothalamic-Pituitary-Testicular Axis

Testicular endocrine and gametogenic functions are governed by the hypothalamic-pituitary-testicular (HPT) axis, a tightly regulated neuroendocrine feedback circuit essential for male sexual differentiation, pubertal maturation, and maintenance of fertility. The axis originates within the arcuate nucleus of the hypothalamus, where gonadotropin-releasing hormone (GnRH)—a decapeptide cleaved from a larger preprohormone precursor—is synthesized and released into the hypothalamic-pituitary portal circulation. GnRH is delivered in discrete, high-frequency pulses to the anterior pituitary gland, where it binds selectively to high-affinity G-protein-coupled receptors on the surface of pituitary gonadotroph cells. Receptor binding activates a phospholipase C-dependent intracellular signaling cascade that drives the synthesis and exocytosis of two principal dimeric gonadotropins: luteinizing hormone (LH) and follicle-stimulating hormone (FSH).

Both LH and FSH are heterodimeric glycoproteins composed of a common $\alpha$-subunit and a unique $\beta$-subunit that confers hormonal specificity. Due to the extremely short half-life of GnRH in peripheral circulation, direct peripheral measurement of GnRH is unfeasible in clinical practice; consequently, the pulsatile dynamics of the hypothalamic pulse generator are inferred through peripheral LH secretor pulses. Experimental and clinical models demonstrate that continuous, non-pulsatile exposure to GnRH or long-acting GnRH agonists leads to receptor desensitization and down-regulation, rapidly suppressing LH and FSH secretion. Conversely, pulsatile administration of exogenous GnRH at physiological intervals ($90\text{ to }120\text{ minutes}$) successfully restores physiological gonadotropin release and downstream testicular activity in GnRH-deficient states.

Steroidogenesis and Metabolic Pathways of Testosterone

Testosterone represents the primary circulating testicular androgen, produced by Leydig cells at an estimated daily rate of $5\text{ to }7\text{ mg}$ in adult men. Testicular steroidogenesis is initiated when circulating LH binds to its specific surface receptor on Leydig cells, activating membrane-bound adenylyl cyclase and raising intracellular cyclic adenosine monophosphate (cAMP) levels. Elevated cAMP promotes the transport of cholesterol across the mitochondrial membrane via the steroidogenic acute regulatory (StAR) protein, where the cholesterol side-chain cleavage enzyme ($\text{P450scc}$) converts cholesterol to pregnenolone. Through a series of enzymatic steps involving $3\beta$-hydroxysteroid dehydrogenase, $17\alpha$-hydroxylase, $17,20$-lyase, and $17\beta$-hydroxysteroid dehydrogenase, pregnenolone is converted into testosterone. Testosterone release follows a circadian pattern in healthy young men, characterized by peak serum concentrations around 08:00 h and a trough around 20:00 h.

In peripheral blood, approximately $98\%\text{ to }99\%$ of circulating testosterone is bound to plasma proteins. High-affinity binding to sex hormone-binding globulin (SHBG) accounts for roughly $40\%$ of circulating testosterone, while $60\%$ is loosely bound to serum albumin. The remaining $1\%\text{ to }2\%$ exists as unprotonated, unbound free testosterone. Because the dissociation constant of albumin-bound testosterone is low, both the free and albumin-bound fractions constitute the bioavailable testosterone pool accessible to peripheral target tissues, whereas SHBG-bound androgen is biologically inactive. Hepatic SHBG synthesis is upregulated by circulating estrogens, thyroid hormones, and advanced age, whereas it is down-regulated by exogenous androgens, growth hormone, insulin, and visceral adiposity.

Once delivered to target organs, testosterone operates through three distinct physiological pathways:

Direct activation of the androgen receptor occurs when unconverted testosterone passively diffuses through cell membranes and binds the intracellular androgen receptor—a ligand-dependent transcription factor encoded by a gene on the X chromosome. Dimerization of the hormone-receptor complex enables binding to specific androgen response elements (AREs) on genomic DNA, recruiting transcriptional coactivators to initiate messenger RNA synthesis. This direct mechanism drives the fetal differentiation of Wolffian duct structures into the epididymis, vas deferens, and seminal vesicles, while in post-pubertal life it promotes skeletal muscle hypertrophy, visceral erythropoiesis, epiphyseal linear bone growth, and central suppression of pituitary LH release.

Enzymatic conversion via $5\alpha$-reduction transforms testosterone into dihydrotestosterone (DHT), a potent androgen possessing a multi-fold higher affinity for the androgen receptor than its parent molecule. Two isoforms of $5\alpha$-reductase exist: Type 1 is localized predominantly in nongenital skin, liver, and sebaceous glands, whereas Type 2 is concentrated within urogenital tissue, genital skin, and the prostate gland. DHT production is responsible for fetal differentiation of the penis, scrotum, and urethra, as well as pubertal facial, body, and pubic hair development, temporal scalp line regression, and prostatic epithelial growth.

Aromatization converts testosterone into $17\beta$-estradiol ($E_2$) through the activity of the cytochrome P450 aromatase enzyme complex, expressed in adipose tissue, vascular endothelium, central nervous system nuclei, liver, and osteocytes. Estradiol exerts essential regulatory actions in the male body by binding to estrogen receptors $\text{ER}\alpha$ and $\text{ER}\beta$. Estrogen signaling is critical for maintaining bone mineral density, stimulating pubertal epiphyseal fusion, regulating central libido, and mediating negative feedback control over pituitary FSH and LH secretion.

Spermatogenesis and the Seminiferous Microenvironment

Spermatogenesis is the complex developmental process by which diploid spermatogonial stem cells undergo mitotic proliferation, meiotic division, and haploid morphological transformation to yield mature spermatozoa within the seminiferous tubules. Intratesticular testosterone concentrations are maintained at levels up to 100-fold higher than those in peripheral circulation. This high local androgenic concentration is essential for maintaining the structural integrity of the seminiferous epithelium and preventing germ cell apoptosis. The local androgen reservoir is generated by Leydig cell secretion and bound within the tubular lumen by androgen-binding protein (ABP), synthesized by Sertoli cells under the direct influence of FSH.

Sertoli cells form adjacent tight junctions that construct the blood-testis barrier, creating an immunologically privileged microenvironment that shields developing post-meiotic germ cells from systemic autoimmune attack. Sertoli cells synthesize paracrine regulators, including activin, which promotes local germ cell proliferation, and inhibin B, which enters systemic circulation to exert selective negative feedback on pituitary FSH release. The entire timeline of human spermatogenesis requires approximately 90 days. Mitotic maturation and meiotic cleavage of a spermatogonium into a spermatozoon within the seminiferous tubule spans roughly 75 days, after which the immotile spermatozoon passes into the epididymis for a 14-day transit, acquiring progressive forward motility and fertilization competence.

Testicular Function Across Life Stages

Testicular function changes throughout life, beginning during early embryogenesis, undergoing transient activation in infancy, reaching maximum functional capacity during pubertal development, and undergoing a slow decline during senescence.

During the first trimester of embryonic development, expression of the sex-determining region Y (SRY) gene on the Y chromosome drives differentiation of the bipotential gonadal ridge into functional primitive testes. Fetal Sertoli cells immediately produce Anti-Müllerian Hormone (AMH), triggering regression of the Müllerian ducts and preventing female internal genital development. Concurrently, placental human chorionic gonadotropin (hCG) stimulates fetal Leydig cells to produce testosterone, promoting survival and differentiation of Wolffian duct structures into male internal genitalia. Local reduction of testosterone to DHT drives differentiation of the urogenital sinus and genital tubercle into the prostate, scrotum, and penis. In the third trimester, fetal pituitary LH secretion stimulates testicular androgen production to drive phallic growth and promote transinguinal migration of the testes into the scrotum.

Within the first few months after birth, a temporary surge of hypothalamic GnRH pulse generator activity occurs, elevating LH, FSH, and testosterone to levels typical of mid-pubertal boys. The precise biological role of this "mini-puberty" remains under investigation, though it is hypothesized to influence germ cell priming and neurodevelopment. Following this transient rise, the HPT axis enters a quiescent state characterized by low gonadotropin and androgen levels until pubertal initiation.

Reactivation of pulsatile hypothalamic GnRH secretion initiates male puberty at a mean age of $11.4 \pm 1.1$ years. The initial physical sign of pubertal onset is an increase in testicular volume from a baseline of less than $2\text{ mL}$ toward an adult average volume of $20\text{ to }25\text{ mL}$, driven by FSH-induced expansion of seminiferous tubules. Rising systemic testosterone concentrations induce phallic elongation, scrotal hyperpigmentation and rugation, pubic and axillary hair growth, laryngeal enlargement with voice deepening, linear skeletal growth acceleration, and an increase in red blood cell mass and total body skeletal muscle. Complete pubertal somatic transformation is generally achieved within 4 to 5 years, though terminal body hair patterning and temporal hair loss continue to evolve over subsequent decades.

Male aging is accompanied by a continuous, gradual decline in Leydig cell steroidogenic capacity alongside alterations in hypothalamic-pituitary pulse dynamics, a process termed male senescence. Serum total testosterone levels decrease slowly with age. Concurrently, serum SHBG levels rise progressively in older men, causing a greater decrease in free and bioavailable testosterone than in total testosterone. Cross-sectional and longitudinal assessments demonstrate that by age 80, mean circulating free testosterone is $33\%\text{ to }50\%$ lower than that observed in 20-year-old men. This decline results from both a reduced population of functional Leydig cells and diminished responsiveness to LH stimulation, alongside blunted hypothalamic GnRH secretor dynamics.

Etiology, Pathophysiology, and Evaluation of Male Hypogonadism

Classification: Primary vs. Secondary Hypogonadism

Male hypogonadism is defined as a clinical syndrome caused by failure of the testes to produce physiological levels of testosterone, mature spermatozoa, or both. Hypogonadism is categorized based on the primary anatomical site of pathology within the HPT axis:

Primary hypogonadism (hypergonadotropic hypogonadism) arises from intrinsic testicular disease affecting the Leydig cells, seminiferous tubules, or both. Impaired testicular steroidogenesis or tubular failure diminishes negative feedback to the central nervous system, leading to elevated serum concentrations of LH and FSH.

Secondary hypogonadism (hypogonadotropic hypogonadism) results from structural, genetic, or functional impairment of the hypothalamus or anterior pituitary gland. Defective GnRH secretion or pituitary gonadotroph failure leads to low or inappropriately normal serum LH and FSH levels despite subnormal circulating testosterone concentrations and depressed sperm counts.

Congenital and Acquired Primary Testicular Disorders

Klinefelter syndrome is the most common genetic cause of primary hypogonadism, occurring in approximately $0.2\%$ (1 in 500) of live male births. The underlying genetic defect is sex-chromosomal non-disjunction during parental meiotic gametogenesis, resulting in a $47,\text{XXY}$ karyotype in the classic form. Mosaic variants, such as $46,\text{XY}/47,\text{XXY}$, arise from post-zygotic mitotic errors and exhibit variable clinical severity.

The additional X chromosome leads to progressive tubular degeneration, germ cell loss, and hyalinization of the seminiferous architecture during pubertal transition. In adult life, patients present with small, firm testes ($<4\text{ mL}$ volume), complete azoospermia, severe elevation of serum FSH, and primary subfertility. Leydig cell impairment is variable; serum total testosterone ranges from normal to subnormal, with elevated serum LH reflecting compensated or uncompensated primary Leydig cell failure. Physical features include eunuchoid proportions, increased lower-segment length due to delayed epiphyseal fusion or gene dosage effects of the SHOXI gene, sparse facial and body hair, a higher incidence of gynecomastia, and variable deficits in verbal and social processing.

Cryptorchidism, or failure of testicular descent into the scrotum, impairs testicular structure and function. Exposure to higher intra-abdominal or inguinal temperatures causes progressive destruction of spermatogonia, while Leydig cells remain relatively preserved. Unilateral cryptorchidism is associated with subnormal sperm density and mild FSH elevation in $25\%\text{ to }33\%$ of patients, whereas bilateral cryptorchidism causes severe oligospermia or azoospermia and elevated risk of hypogonadism. Cryptorchid testes also carry a 2- to 5-fold higher risk of developing testicular germ cell tumors.

Varicocele consists of abnormal dilatation and tortuosity of the pampiniform venous plexus within the spermatic cord, occurring predominantly on the left side. The traditional pathophysiology posits that venous incompetence leads to retrograding blood flow, elevating scrotal temperatures and impairing spermatogenesis via oxidative stress and microvascular hypoxia. However, scrotal temperature elevations are inconsistently correlated with semen parameters, and randomized trials assessing varicocelectomy demonstrate variable fertility improvement. Consequently, routine surgical varicocele repair to treat subfertility remains controversial and is reserved for palpable clinical varicoceles accompanied by verified semen abnormalities.

Defects in androgen biosynthesis stem from rare enzymatic gene mutations along the steroidogenic pathway. Congenital deficiencies of $3\beta$-hydroxysteroid dehydrogenase or $17\alpha$-hydroxylase affect both adrenal and gonadal steroid production, causing concurrent adrenal insufficiency and severe virilization defects in utero. Isolated $17\beta$-hydroxysteroid oxidoreductase deficiency disrupts the testicular conversion of androstenedione to testosterone, leading to inadequate intra-uterine virilization and ambiguous external genitalia at birth. Microdeletions in the azoospermia factor (AZF) regions ($AZFa$, $AZFb$, $AZFc$) on the long arm of the Y chromosome cause isolated primary spermatogenic failure, manifesting clinically as non-obstructive azoospermia or severe oligospermia without primary Leydig cell failure.

Acquired testicular injury can result from infectious, cytotoxic, or traumatic insults:

Viral orchitis, most commonly caused by the mumps paramyxovirus, develops in up to $30\%$ of post-pubertal males with systemic mumps. Acute infection manifests as painful swelling, leukocyte infiltration, and edema, which can lead to seminiferous tubule atrophy and testicular atrophy. While unilateral mumps orchitis may spare fertility through contralateral compensation, bilateral infection often causes permanent azoospermia and Leydig cell dysfunction.

Cytotoxic chemotherapy, particularly with alkylating agents such as cyclophosphamide and melphalan, damages actively dividing spermatogonia. Radiation therapy to the pelvis or inguinal lymph nodes similarly causes dose-dependent destruction of the germinal epithelium due to direct irradiation or scattered exposure. Spermatogenic recovery depends on the cumulative cytotoxic dose and the survival of primary spermatogonial stem cells.

Direct trauma, severe testicular torsion leading to ischemic necrosis, and medical castration (bilateral orchiectomy or chemical ablation for advanced prostate carcinoma) represent primary causes of functional or anatomical anorchia. Additionally, chronic ingestion of ketoconazole directly inhibits cytochrome P450 enzymes required for steroidogenesis, while heavy alcohol abuse exerts direct toxic effects on germ cells and Leydig cell membranes. Chronic HIV infection and AIDS wasting syndrome contribute to hypogonadism through a combination of cytokine-mediated primary Leydig cell injury, opportunistic infections, malnutrition, and antiretroviral toxicities.

Secondary Hypogonadotropic Disorders

Congenital isolated hypogonadotropic hypogonadism results from genetic defects that disrupt GnRH neuronal migration, GnRH synthesis, or gonadotroph receptor activity.

Kallmann syndrome represents the best-characterized form of congenital hypogonadotropic hypogonadism, defined by the co-occurrence of central hypogonadism and anosmia or hyposmia. The classic X-linked recessive form is caused by loss-of-function mutations in the KAL-1 gene, which encodes anosmin-1—an extracellular matrix glycoprotein that guides the embryonic co-migration of olfactory axons and GnRH-secreting neurons from the nasal olfactory placode to the arcuate nucleus. Disruption of this migratory pathway results in hypoplastic or absent olfactory bulbs and failure of GnRH innervation within the hypothalamus. Patients present with complete or partial pubertal failure, eunuchoid body habitus, microphallus, cryptorchidism, and an inability to perceive odors. Autosomal dominant and recessive variants involving FGFR1, PROKR2, and PROK2 pathways have also been identified.

Genetic variants causing central hypogonadism without olfactory deficits include inactivating mutations of the GnRH receptor (GNRHR) gene, which render pituitary gonadotrophs non-responsive to endogenous GnRH pulses. Mutations in the DAX-1 (NR0B1) gene cause X-linked adrenal hypoplasia congenita combined with hypogonadotropic hypogonadism, while rare mutations in the $\text{LH}\beta$ or $\text{FSH}\beta$ subunit genes cause selective gonadotropin deficiencies.

Acquired secondary hypogonadism can result from mass lesions, infiltrative processes, structural damage, or pharmacological suppression:

Sellar and parasellar mass lesions—including non-functioning pituitary adenomas, prolactinomas, craniopharyngiomas, Rathke pouch cysts, meningiomas, and metastatic tumors—can compress gonadotroph cells or disrupt the hypothalamic-pituitary stalk. Hyperprolactinemia, caused by prolactin-secreting lactotroph adenomas or stalk compression, directly inhibits hypothalamic GnRH pulse generator activity.

Systemic infiltrative diseases, such as sarcoidosis, Langerhans cell histiocytosis, and systemic hemochromatosis (which causes selective iron deposition within pituitary gonadotroph cells), damage central gonadotropin-releasing pathways. Structural damage following neurosurgical procedures, cranial irradiation, or traumatic brain injury can similarly impair central HPT function.

Pharmacological suppression of the HPT axis occurs with chronic high-dose glucocorticoid therapy, megestrol acetate, and long-term opioid use. Exogenous opioids bind $\mu$-opioid receptors in the hypothalamus, inhibiting GnRH secretion and causing secondary hypogonadism in chronic pain patients and individuals with opioid use disorder. Severe systemic illness, starvation, severe caloric restriction, and uncontrolled diabetes mellitus can also reversibly suppress central GnRH release.

Late-Onset Hypogonadism (LOH) and Metabolic Comorbidities

Late-Onset Hypogonadism (LOH) is a clinical and biochemical condition in aging men characterized by low circulating testosterone in combination with characteristic systemic symptoms. The prevalence of LOH increases with advancing age, ranging from $2.1\%\text{ to }5.7\%$ in community-dwelling men aged 40 to 79 years.

Pathophysiologically, LOH involves both testicular and hypothalamic-pituitary dysfunction. It is strongly associated with metabolic syndrome, visceral obesity, and type 2 diabetes mellitus. Visceral adipose tissue expresses high levels of aromatase, which converts circulating testosterone to estradiol, enhancing central negative feedback on GnRH and LH secretion. In addition, visceral adiposity increases pro-inflammatory cytokines such as TNF-$\alpha$ and IL-6, which directly impair Leydig cell function and suppress hypothalamic GnRH release. Conversely, lower testosterone levels promote visceral adipocyte hypertrophy, reduce lean muscle mass, decrease basal metabolic rate, and worsen insulin resistance. This creates a bidirectional pathological loop linking hypogonadism to metabolic disease.

Visceral Adiposity & Inflammatory Cytokines (TNF-α, IL-6)

        │

        ├─────────────────────────────────────────┐

        ▼                                         ▼

Increased Aromatase Expression            Direct Testicular Leydig Cell Impairment

        │                                         │

        ▼                                         │

Conversion of Testosterone to Estradiol          │

        │                                         │

        ▼                                         │

Enhanced Central Feedback (GnRH/LH Suppression)   │

        │                                         │

        └────────────────────┬────────────────────┘

                             │

                             ▼

                Suppressed Testosterone Synthesis

                             │

                             ▼

         Decreased Muscle Mass & Increased Adiposity

Clinical Presentation and Diagnostic Algorithm

The clinical presentation of testosterone deficiency depends on the timing, duration, and severity of androgen deprivation. When deficiency occurs during early fetal development, it disrupts external genital virilization, resulting in ambiguous genitalia or hypospadias. Deficiency during the third trimester impairs penile growth, presenting at birth as microphallus. Pre-pubertal onset delays pubertal progression, leading to persistent eunuchoid skeletal proportions, sparse facial and body hair, lack of voice deepening, microphallus, and infantile testicular volume.

Post-pubertal onset of hypogonadism produces more subtle and variable clinical features. Loss of libido, reduced frequency of spontaneous morning erections, and erectile dysfunction typically develop within weeks of falling testosterone levels. Lethargy, fatigue, low mood, and reduced motivation occur early, whereas decreased muscle mass, reduced bone mineral density, and sparse body hair develop over several years.

Evaluating suspected hypogonadism requires a structured diagnostic approach:

                            Clinical Suspicion of Hypogonadism

                         (Symptoms: Low Libido, ED, Fatigue, Low BMD)

                                             │

                                             ▼

                      Fasting Serum Total Testosterone (08:00–10:00 h)

                                             │

                   ┌─────────────────────────┴─────────────────────────┐

                   ▼                                                   ▼

         Total T > 317 ng/dL                                 Total T < 317 ng/dL

         (12.1 nmol/L)                                       (12.1 nmol/L)

                   │                                                   │

                   ▼                                                   ▼

            Normal State                                   Repeat Fasting Total T

                                                         + SHBG / Calculate Free T

                                                                       │

                                                                       ▼

                                                          Confirmed Biochemical Low T

                                                                       │

                                             ┌─────────────────────────┴─────────────────────────┐

                                             ▼                                                   ▼

                                    Elevated LH and FSH                                 Low or Normal LH/FSH

                                             │                                                   │

                                             ▼                                                   ▼

                                   Primary Hypogonadism                                Secondary Hypogonadism

                                             │                                                   │

                            ┌────────────────┴────────────────┐                 ┌────────────────┴────────────────┐

                            ▼                                 ▼                 ▼                                 ▼

                   Karyotype Analysis                Scrotal Ultrasound     Sellar MRI                    Prolactin & Iron

                   (Rule out 47,XXY)                 (Tumor/Cryptorchid)   (Rule out mass)                (Exclude Hemochromatosis)

1. Serum Testosterone Measurement: Total serum testosterone must be measured from a blood sample drawn between 08:00 and 10:00 h in a fasted state to coincide with peak diurnal secretion. Diagnosis requires confirmation with at least two separate low total testosterone measurements using a validated assay. Consensus guidelines define biochemical deficiency as total testosterone $<317\text{ ng/dL}$ ($12.1\text{ nmol/L}$) or free testosterone $<8.9\text{ ng/dL}$ ($220\text{ pmol/L}$). If SHBG abnormalities are suspected—such as in patients with obesity, liver disease, or advanced age—free testosterone should be calculated or measured directly using equilibrium dialysis.
2. Gonadotropin Assessment: Serum LH and FSH concentrations differentiate primary testicular failure (elevated gonadotropins) from secondary hypothalamic-pituitary pathology (low or inappropriately normal gonadotropins). Isolated elevation of FSH with normal LH indicates selective damage to the seminiferous tubules with preserved Leydig cell function.
3. Etiological Workup: Secondary hypogonadism warrants sellar Magnetic Resonance Imaging (MRI) to evaluate for structural mass lesions, alongside serum prolactin, transferrin saturation, and ferritin testing. Primary hypogonadism in patients with small testes or eunuchoid features warrants karyotype analysis to rule out Klinefelter syndrome.

Therapeutic Management and Clinical Pharmacology

Testosterone Replacement Therapy (TRT)

The primary objective of Testosterone Replacement Therapy (TRT) is to restore serum testosterone levels to the mid-normal physiological range, relieving hypogonadal symptoms, maintaining bone mineral density, improving body composition, and supporting overall quality of life.

Pharmacological Formulations and Delivery Systems

Intramuscular testosterone esters, such as testosterone enanthate and testosterone cypionate, are esterified at the $17\beta$-hydroxyl position with fatty acid chains to delay absorption from the intramuscular oil depot. Administered at doses of $150\text{ to }200\text{ mg}$ every 2 weeks, these agents produce supraphysiological serum testosterone peaks within 24 to 48 hours post-injection, followed by a gradual decline to subnormal nadir levels prior to the next injection. These wide pharmacokinetic fluctuations can cause parallel swings in patient energy, mood, hematocrit, and libido.

Transdermal gel formulations ($50\text{ to }100\text{ mg}$ applied daily) and transdermal patches provide steady transdermal absorption, yielding serum testosterone concentrations within the physiological range that mimic normal diurnal rhythms. Gels avoid the pronounced peak-and-trough fluctuations seen with injectable esters, resulting in stable improvements in energy, mood, and sexual function. However, transdermal gels carry a risk of interpersonal transfer through direct skin contact, requiring precautions after application.

Oral $17\alpha$-alkylated synthetic derivatives, such as methyltestosterone and fluoxymesterone, resist hepatic first-pass metabolism. However, they offer weak virilizing efficacy and carry significant risks of severe hepatotoxicity, including cholestatic jaundice, peliosis hepatis, and hepatocellular carcinoma. 17$\alpha$-alkylated formulations are contraindicated for the treatment of male hypogonadism.

Monitoring Protocols and Safety Profiles

Monitoring during TRT is required to evaluate therapeutic efficacy and detect potential adverse effects:

Therapeutic efficacy is monitored by measuring fasting serum total testosterone levels, aiming for the mid-normal physiological range. For patients receiving injectable esters, levels should be checked midway between injections, whereas for transdermal gel users, testing can occur at any time during routine daily application.

Prostate health monitoring is recommended in men over 40 years of age, including baseline and periodic serum Prostate-Specific Antigen (PSA) measurements and Digital Rectal Examination (DRE). While exogenous testosterone does not cause de novo prostate cancer, it can stimulate pre-existing androgen-dependent prostate tissue.

Hematologic safety requires measuring hematocrit at baseline, at 3 to 6 months after initiating therapy, and annually thereafter. Erythrocytosis (defined as a hematocrit $>54\%$) increases blood viscosity and thromboembolic risk, warranting dose reduction, transition to transdermal delivery, or therapeutic phlebotomy.

Cardiovascular risk assessments from recent systematic reviews and updated EAU guidelines indicate that appropriately monitored TRT in hypogonadal men does not increase the risk of major adverse cardiovascular events.

Stimulation of Spermatogenesis

Exogenous testosterone therapy suppresses pituitary LH and FSH secretion via central negative feedback, impairing intratesticular steroidogenesis and suppressing spermatogenesis. Consequently, exogenous testosterone should not be used in men desiring current or near-term fertility.

For men with secondary hypogonadism seeking fertility restoration, gonadotropin therapy can induce spermatogenesis:

Human chorionic gonadotropin (hCG), which acts as an LH analog, is administered at doses of $1500\text{ to }2500\text{ IU}$ subcutaneously two to three times weekly to stimulate Leydig cell intratesticular testosterone synthesis. If sperm do not appear in the ejaculate after several months of hCG monotherapy, recombinant FSH or human menopausal gonadotropin (hMG) is added to stimulate Sertoli cell function and support germ cell maturation.

Pulsatile subcutaneous GnRH therapy delivered via a specialized micro-infusion pump offers an alternative approach for patients with hypothalamic GnRH deficiency and intact pituitary gonadotroph function (such as Kallmann syndrome), successfully restoring gonadotropin release and spermatogenesis.

In primary hypogonadism, hormonal therapy cannot induce spermatogenesis due to intrinsic testicular damage. In these cases, surgical sperm retrieval techniques—such as microdissection testicular sperm extraction (micro-TESE)—combined with intracytoplasmic sperm injection (ICSI) are required for assisted reproduction.

Disorders of Androgen Action, Structural Pathology, and Sexual Dysfunction

Pathophysiology of Androgen Resistance

Disorders of androgen action result from genetic mutations that disrupt androgen receptor structure or peripheral $5\alpha$-reductase activity, causing variable deficits in target tissue virilization despite normal or elevated circulating testosterone levels.

Complete Androgen Insensitivity Syndrome (CAIS) is caused by inactivating mutations in the X-linked androgen receptor gene, preventing target tissue responsiveness to circulating androgens. Affected $46,\text{XY}$ individuals possess functional testes that secrete normal levels of AMH, leading to regression of internal Müllerian duct structures. However, complete lack of androgen signaling prevents Wolffian duct development and external genital virilization, resulting in female external genitalia at birth. At puberty, elevated LH levels drive high testicular testosterone production. Unopposed peripheral aromatization of testosterone to estradiol stimulates breast development, while pubic and axillary hair remain absent or sparse.

Partial Androgen Insensitivity Syndrome (PAIS) results from mutations that partially impair androgen receptor function, producing a wide phenotypic spectrum ranging from ambiguous genitalia and severe hypospadias to isolated adult male subfertility.

Spinal and Bulbar Muscular Atrophy (Kennedy Disease) is an X-linked neuromuscular disorder caused by expansion of a CAG trinucleotide repeat sequence in the androgen receptor gene. Patients develop progressive motor neuron degeneration, muscle weakness, and bulbar palsy, accompanied by mild androgen resistance manifesting as pubertal gynecomastia and subfertility.

$5\alpha$-Reductase Type 2 Deficiency results from mutations in the SRD5A2 gene, impairing the conversion of testosterone to DHT in urogenital tissue. $46,\text{XY}$ infants present with female or ambiguous external genitalia and are frequently assigned female gender at birth. At puberty, high circulating testosterone levels partially overcome the enzyme defect, causing phallic growth, testicular descent, voice deepening, and muscle development. Early molecular diagnosis is crucial to guide appropriate medical, surgical, and psychosocial management.

Gynecomastia

Gynecomastia is the benign enlargement of male breast glandular tissue caused by an increased effective ratio of active estrogens to androgens.

Systemic physiological and pathological mechanisms include:

• Elevated Endogenous Estrogens: Primary hypogonadism increases LH secretion, stimulating intratesticular aromatase activity and increasing estradiol production relative to testosterone. hCG-secreting germ cell tumors markedly enhance testicular estrogen release through direct gonadal stimulation.
• Increased Peripheral Conversion: Adipose tissue accumulation in obesity increases total body aromatase capacity. In liver cirrhosis, reduced hepatic clearance of adrenal androstenedione provides increased substrate for peripheral conversion to estrone.
• Inhibition of Androgen Action: Pharmacological agents such as spironolactone, cimetidine, flutamide, bicalutamide, and cyproterone acetate compete with endogenous testosterone for androgen receptor binding, reducing androgen signaling while permitting peripheral estrogenic action on breast tissue.

Diagnosis is confirmed by physical examination using the caliper technique: placing the spread thumb and forefinger on opposite sides of the breast and bringing them together toward the nipple. True gynecomastia presents as a firm, cohesive disc of glandular tissue centered directly beneath the nipple-areolar complex, whereas pseudogynecomastia (lipomastia) consists of soft, diffuse fat deposition without palpable glandular tissue. Breast tenderness suggests recent-onset glandular proliferation. Unilateral, hard, eccentric masses fixed to underlying tissue warrant evaluation to rule out male breast carcinoma. Management involves treating underlying medical conditions or discontinuing causative medications. Long-standing fibrous gynecomastia rarely regresses spontaneously, and surgical excision remains the definitive treatment for persistent, symptomatic cases.

Erectile Dysfunction and Interplay with Testicular Hormones

Erectile dysfunction (ED) is defined as the persistent inability to attain or maintain a penile erection sufficient for satisfactory sexual performance.

Erection is a neurovascular process initiated by sensory or psychogenic inputs. Central erotic stimuli trigger parasympathetic signals via pelvic splanchnic nerves, stimulating endothelial nitric oxide synthase (eNOS) and neuronal nitric oxide synthase (nNOS) to synthesize nitric oxide (NO) within cavernosal tissue. NO diffuses into cavernosal vascular smooth muscle cells, activating guanylate cyclase to convert GTP into cyclic guanosine monophosphate (cGMP). Elevated intracellular cGMP promotes smooth muscle relaxation, increasing arterial blood flow into the corpora cavernosa and compressing subtunical venules to restrict venous outflow.

Testosterone deficiency reduces sexual desire, sexual thoughts, and nocturnal penile erections. However, hypogonadism alone is rarely the sole cause of ED in men with normal libido. ED is more commonly driven by vascular disease (atherosclerosis, endothelial dysfunction), autonomic neuropathy (diabetes mellitus), structural nerve injury (radical prostatectomy), or psychogenic factors. First-line pharmacological treatment for ED relies on phosphodiesterase type 5 (PDE5) inhibitors, such as sildenafil, which inhibit cGMP degradation in cavernosal tissue, preserving smooth muscle relaxation and arterial inflow. Second-line therapies include intraurethral alprostadil suppositories, intracavernosal prostaglandin $E_1$ injections, or vacuum erection devices.

Conclusions

Testicular function depends on the coordinated regulation of the hypothalamic-pituitary-testicular axis. Leydig cell steroidogenesis produces systemic testosterone and high local intratesticular concentrations necessary for Sertoli-cell-mediated spermatogenesis. Testicular disorders encompass a broad spectrum of pathology, ranging from congenital genetic conditions such as Klinefelter syndrome and Kallmann syndrome to acquired infectious, cytotoxic, structural, and metabolic insults.

Contemporary guidelines highlight Late-Onset Hypogonadism as a clinical and biochemical condition closely linked with metabolic comorbidities, particularly visceral obesity and type 2 diabetes. Diagnostic evaluation requires a systematic approach, including repeated early morning fasting total and free testosterone measurements combined with LH and FSH assessment to differentiate primary from secondary etiology.

Therapeutic management must be tailored to patient goals:

• Transdermal testosterone formulations offer steady physiological delivery for symptomatic hypogonadism.
• Oral $17\alpha$-alkylated synthetics are contraindicated due to risk of severe hepatotoxicity.
• In men seeking fertility preservation, exogenous testosterone should be avoided; gonadotropin therapy or pulsatile GnRH administration is required to stimulate spermatogenesis.

Ongoing research into selective androgen receptor modulators, metabolic interventions, and advanced micro-surgical retrieval techniques promises to further refine clinical management for men with testicular disorders.